Latest Selective immunoglobulin A deficiency Stories
KING OF PRUSSIA, Pa., March 21, 2011 /PRNewswire/ -- Data presented by CSL Behring today suggest that treatment with higher dose HizentraÂ® (IgPro 20) correlates with reduced risk of infection and missed school or work among patients with primary immunodeficiencies (PI).
KING OF PRUSSIA, Pa., March 19, 2011 /PRNewswire/ -- CSL Behring today announced the development of an innovative pharmacokinetic (PK) model that allows the absorption, distribution, metabolism, and elimination of subcutaneous (SC) immunoglobulin G (IgG) following administration to be simulated with a high degree of accuracy and precision.
DEERFIELD, Ill. and SAN DIEGO, Jan. 5 /PRNewswire-FirstCall/ -- Baxter International Inc. and Halozyme Therapeutics, Inc.
DEERFIELD, Ill., Sept. 22 /PRNewswire-FirstCall/ -- Baxter Healthcare Corporation today announced initiation of a Phase III clinical trial following U.S.
By Maher, Kevin J Between 9,000 and 4,000 BC, in the age when glaciers melted and the earth warmed, nomadic hunter-gatherers settled down to more agrarian pursuits and began to cultivate wheat as a source of food.
- A political dynamiter.